Compare CLW & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLW | IFRX |
|---|---|---|
| Founded | 1926 | 2007 |
| Country | United States | Germany |
| Employees | 3710 | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.7M | 303.4M |
| IPO Year | 2008 | 2017 |
| Metric | CLW | IFRX |
|---|---|---|
| Price | $19.45 | $1.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $21.50 | $7.77 |
| AVG Volume (30 Days) | 102.2K | ★ 444.7K |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,555,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.42 | N/A |
| 52 Week Low | $11.73 | $0.80 |
| 52 Week High | $23.59 | $2.95 |
| Indicator | CLW | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 40.02 |
| Support Level | $19.25 | $1.58 |
| Resistance Level | $20.80 | $2.38 |
| Average True Range (ATR) | 0.83 | 0.12 |
| MACD | -0.22 | -0.03 |
| Stochastic Oscillator | 15.17 | 14.00 |
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.